| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.1 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.073 | 0.1 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.1 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |